Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years
• To describe the immune response of each candidate vaccine 21 days after each vaccination by HAI and SN testing in all subjects. • To describe the safety profiles (injection site reactions, and syste...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis (Poland)
Update Il y a 4 ans
Influence of active awareness about venous thromboembolism relevance and rate of symptomatic deep vein thrombosis
Background and study aims Deep vein thrombosis (DVT) is a blood clot that develops within a deep vein in the body, usually in the leg, causing cause pain and swelling. The symptoms of DVT are not spec...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
TCD12128 : Essai de phase 1-2 évaluant la dose maximale tolérée du cabazitaxel associé à de l’acétate d’abiratérone et de la prednisone, chez des patients ayant un cancer de la prostate métastatique résistant à la castration et en progression après une première ligne de chimiothérapie par docétaxel. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la dose la mieux adaptée de cabazitaxel, à administrer en association avec de l’acétate d’abiratérone et de la prednisone, chez des patients ayant un cancer de la...
Country
France
organs
Prostate
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Safety and Immunogenicity of Sanofi Pasteur’s DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Primary Series of Vaccination in Infants
To describe the safety and reactogenicity after each and all doses of the study vaccine administered as a 3-dose primary series.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis (UK)
Update Il y a 4 ans
32-week, multicentre, open, randomised, two-way cross-over, clinical trial comparing insulin glargine (HOE 901) in combination with insulin lispro and neutral protamine Hagedorn in combination with regular human insulin in subjects with type one diabetes mellitus on a meal-time and basal insulin regimen
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depressive symptoms in patients with major depressive disorder improved after 8 months of open treatment with SR58611A (350 mg q12)
To assess the efficacy of SR58611A 350 mg q12 compared to placebo in the prevention of relapse / recurrence of depressive symptoms, in sustained responder patients with major depressive disorder, over...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-aventis
Update Il y a 4 ans
A clinical trial to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain. Klinikai vizsgálat a nem múló daganatos fájdalom kiegészítő kezelésére alkalmazott SSR411298 készítmény klinikai előnyeinek értékelésére
• To evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain, as measured by the change from baseline (baseline = average pain intensity ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis EFC10145 : Essai de phase 2-3 randomisé en double-aveugle, comparant l'efficacité d'un traitement par du cisplatine associé ou non à de l'AVE8062 chez des patients ayant un sarcome des tissus mous avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A Multinational, randomized, double-blind placebo controlled study of AVE8062 (25 mg/m2) administered every 3 weeks in patients with advanced-stage soft tissue sarcoma, treated with cisplatin (75 mg) ...
Country
France
organs
Sarcomes
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Aventis Research Grant
Update Il y a 4 ans
A phase II/III randomised trial comparing Epirubicin, Cisplatin and Protracted Venous Infusion (PVI) 5-Fluorouracil (5-FU) (ECF), Epirubicin, Oxaliplatin and PVI 5-FU (EOF), Epirubicin, Cisplatin and Capecitabine (ECX) and Epirubicin, Oxaliplatin and Capecitabine (EOX) in Patients with Advanced Oesophago-Gastric Cancer
Not provided at time of registration
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) when administered to Children in their Second Year of Life
To describe the safety profile of a second dose of ProQuad® manufactured with rHA when administered to children in their second year of life
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
11
12
13
14
15
16
17
18
19
20
Next